Last reviewed · How we verify
Systemic
At a glance
| Generic name | Systemic |
|---|---|
| Sponsor | Fraunhofer-Institute of Toxicology and Experimental Medicine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases (PHASE3)
- Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
- Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
- Descartes-08 for Patients With Systemic Lupus Erythematosus (PHASE2)
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- Conception of an ICF Core Set for Systemic Sclerosis
- Pre-Post Multimodal Assessment Of Severe Psoriasis Vulgaris Using Clinical, Dermoscopic And QoL Measures
- A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |